… treatment of breast cancer using Herceptin in HER2- positive patients.7 Pharmaceutical biotechnology … continues to construct the future of medicine, … Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des …

… Medicines Agency’s Committee for Medicinal … trial showed that Minjuvi combined with rituximab … Drug Administration in combination with lenalidomide and rituximab for the treatment … HEALTH CLINICAL TRIALS GENERAL HEALTH PHARMACEUTICAL BIOTECHNOLOGY SOURCE: …

… assistant professor of clinical medicine at Indiana University Health … assistant professor of clinical medicine at the University … cytometry, they explained. Treatment initiation is reserved for … rituximab (BR) in patients with treatment-naive CLL. The trial …

… nonchemotherapy regimen in older and medically unfit patients with diffuse large … receive R-CHOP chemotherapy received rituximab (Rituxan; Genentech, Biogen), polatuzumab … /recruiting trials, guidelines Clinical Guidance, Healio CME, FDA news Healio…

… establishing their role in earlier treatment lines through combination therapies. Patel … ; The trial evaluated epcoritamab (Epkinly) combined with lenalidomide (Revlimid) and rituximab (Rituxan … existing options. Head-to-head trials against approved CD19 CAR T …

… causing the disorder. The registrational trial, designed to generate data for … other immune-suppressing drugs, the company said. The treatment was generally well … like intravenous immunoglobulin, steroids or rituximab, if symptoms persist. Kyverna plans …

… registrational Phase 2 trial of mivocabtagene autoleucel … Medicine Advanced Therapy and Orphan Drug … treatments, off-label immunotherapies, such as intravenous immunoglobulin (IVIg), rituximab … FDA or other regulatory agencies may require additional trials …

… of the phase 3 ECHO trial (NCT02972840) and highlights … seen a lot of community doctors [who are] already … questioning whether using 3 drugs together was better than … to third-line treatment after bendamustine-rituximab with or without acalabrutinib …

… outcomes. Recently, drugs indicated for pulmonary … treatment responses,” he explained. Expanding therapeutic options — but limited accessibility New pharmaceutical … -scale clinical trials confirming strong efficacy … noted. Regarding rituximab, he cited emerging …

… inhibitor zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia. The … patients who received bendamustine and rituximab; and the nonrandomized Arm C …